Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPCP: Convalescent Plasma for Moderate+ COVID-19
NCT04521036Phase 1Completed
- Sponsor
- Vinmec Research Institute of Stem Cell and Gene Technology
- Start
- Dec 2020
- Primary completion
- Jun 2021
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Convalescent Plasma with Standard of Care (2 arms). Primary endpoint: Change in mortality up to 60 days. Started Dec 2020; status: completed.
02
Drugs
convalescent plasma (Heinrich-Heine University, Duesseldorf)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04521036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04521036.